Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients
Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients
复制标题
DOI：
10.1038/s41598-018-36321-3
复制
发表时间：
2018-12-19
影响因子：
4.6
通讯作者：
Omranipour, Ramesh
中科院分区：
文献类型：
--
作者：
Khalighfard, Solmaz;Alizadeh, Ali Mohammad;Omranipour, Ramesh
迫切需要进一步的研究来分类和验证乳腺癌患者的循环microRNAs(MiRs)，这可能是癌症筛查和监测的新策略之一。本研究旨在探讨非转移性乳腺癌患者手术、化疗、放疗后循环候选microRNAs的表达情况。肿瘤组织和血浆样本来自30例新近诊断为A腔乳腺癌的患者。对照血浆样本来自10名健康受试者。选择miR-21、miR-55、miR-10b和let-7a 4个miR，采用实时定量聚合酶链式反应技术检测它们在手术、化疗和放疗前后的表达水平。乳腺癌患者与对照组相比，miR-21、miR-155、miR-10b的血浆表达显著增加，let-7a的血浆表达明显降低。组织和血浆中miRs的表达模式相似。手术、化疗、放疗后血浆miR-21、miR-155、miR-10b水平显著下调，let-7a血浆水平显著上调。手术、化疗、放疗相互妥协后miR-155血浆水平差异有统计学意义。此外，放疗减退后血浆MIR水平与对照组相比无显著差异。手术、化疗和放疗导致肿瘤抑制率进一步降低，肿瘤抑制率升高。在治疗过程中监测MIR似乎可以被认为是监测乳腺癌患者的一种值得尊敬的诊断工具。
There is a pressing need for further studies to categorize and validate circulating microRNAs (miRs) in breast cancer patients that can be one of the novel strategies for cancer screening and monitoring. The present study is aimed to investigate the expression of the circulating candidate microRNAs after the operation, chemotherapy, and radiotherapy in the non-metastatic breast cancer patients. Tumor tissue and plasma samples were collected from the 30 patients with recently diagnosed Luminal A breast cancer. Control plasma samples were collected from the 10 healthy subjects. A panel of four miRs including miR-21, miR-55, miR-10b, and Let-7a were selected and their expression levels were measured before and after the operation, chemotherapy, and radiotherapy by using Real-Time PCR technique. The plasma expression of the miR-21, miR-155, and miR-10b was significantly increased and the Let-7a plasma expression decreased in the breast cancer patients compromised to the control ones. There was a similar expression pattern of the miRs between the tissue and plasma samples. The plasma levels of the miR-21, miR-155, and miR-10b were significantly down-regulated and the Let-7a plasma level was up-regulated after the operation, chemotherapy, and radiotherapy compromised to the pre-treatment. There was a significant difference in the miR-155 plasma level after the operation, chemotherapy, and radiotherapy compromised with each other. Moreover, there was no significant difference between the plasma levels of the miRs after the radiotherapy compromised to the control cases. The operation, chemotherapy, and radiotherapy led to a more reduction in the oncomiRs and an increase in the tumor suppressor-miRs. It seems that monitoring miRs during treatment might be considered as a respectable diagnostic tool for monitoring of breast cancer patients.